Compare SBSW & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBSW | SYRE |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 8.5B |
| IPO Year | 2019 | 2015 |
| Metric | SBSW | SYRE |
|---|---|---|
| Price | $12.13 | $95.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $19.93 | ★ $85.08 |
| AVG Volume (30 Days) | ★ 4.8M | 795.7K |
| Earning Date | 02-20-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $43.55 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.10 | $14.51 |
| 52 Week High | $21.29 | $110.18 |
| Indicator | SBSW | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 71.25 | 38.06 |
| Support Level | $11.03 | $66.78 |
| Resistance Level | $12.37 | $106.10 |
| Average True Range (ATR) | 0.30 | 4.57 |
| MACD | 0.19 | -1.11 |
| Stochastic Oscillator | 79.47 | 12.26 |
Sibanye Stillwater Ltd is a South African mining and metals processing group with a diverse portfolio of operations, projects, and investments across five continents. The Group is also one of the foremost recyclers of PGM autocatalysts and has interests in mine tailings retreatment operations. It is a producer of platinum, palladium, and rhodium and is a top-tier gold producer. It also produces and refines iridium and ruthenium, nickel, chrome, copper, and cobalt. Its products are Gold, Nickel, Zinc, Chrome, PGMs, and other. Group operations are divided into two segments, South African Operations and International and recycling operations.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.